Literature DB >> 21204711

HER2: biology, detection, and clinical implications.

Carolina Gutierrez1, Rachel Schiff.   

Abstract

CONTEXT: HER2 is a membrane tyrosine kinase and oncogene that is overexpressed and gene amplified in about 20% of breast cancers. When activated it provides the cell with potent proliferative and antiapoptosis signals and it is the major driver of tumor development and progression for this subset of breast cancer. When shown to be overexpressed or amplified by appropriate methods, HER2 is a valuable treatment target.
OBJECTIVES: To review the basic biology of the HER2 signaling network, to discuss various approved methods for its detection in clinical specimens, and to describe the impressive results of therapies targeting HER2. DATA SOURCES: Selected literature searchable on PubMed as well as older studies revealed by the literature review were reviewed.
CONCLUSION: HER2 is an important member of a complex signaling network and when gene amplified, it results in an aggressive subtype of breast cancer. Patients with tumors found to overexpress HER2 protein or to be amplified for the gene are candidates for therapy that significantly reduces mortality.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21204711      PMCID: PMC3242418          DOI: 10.5858/2010-0454-RAR.1

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  73 in total

1.  Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers.

Authors:  Dennis J Slamon; Michael F Press
Journal:  J Natl Cancer Inst       Date:  2009-04-28       Impact factor: 13.506

2.  Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.

Authors:  Lavinia P Middleton; Kathy M Price; Pamela Puig; Lori J Heydon; Emily Tarco; Nour Sneige; Kaye Barr; Michael T Deavers
Journal:  Arch Pathol Lab Med       Date:  2009-05       Impact factor: 5.534

3.  HER2 status and benefit from adjuvant trastuzumab in breast cancer.

Authors:  Soonmyung Paik; Chungyeul Kim; Norman Wolmark
Journal:  N Engl J Med       Date:  2008-03-27       Impact factor: 91.245

4.  Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer.

Authors:  Giuseppe Viale
Journal:  J Pathol       Date:  2009-09       Impact factor: 7.996

5.  A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.

Authors:  Yining Shi; Weidong Huang; Yuping Tan; Xueguang Jin; Rajiv Dua; Elicia Penuel; Ali Mukherjee; Jeff Sperinde; Herjit Pannu; Ahmed Chenna; Lisa DeFazio-Eli; Sailaja Pidaparthi; Youssouf Badal; Gerald Wallweber; Lili Chen; Steve Williams; Hasan Tahir; Jeff Larson; Laurie Goodman; Jeannette Whitcomb; Christos Petropoulos; John Winslow
Journal:  Diagn Mol Pathol       Date:  2009-03

6.  Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH.

Authors:  Christine Desmedt; Jeff Sperinde; Fanny Piette; Weidong Huang; Xueguang Jin; Yuping Tan; Virginie Durbecq; Denis Larsimont; Rosa Giuliani; Colombe Chappey; Marc Buyse; John Winslow; Martine Piccart; Christos Sotiriou; Christos Petropoulos; Michael Bates
Journal:  Diagn Mol Pathol       Date:  2009-03

7.  Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.

Authors:  S Shousha; D Peston; B Amo-Takyi; M Morgan; B Jasani
Journal:  Histopathology       Date:  2009-01       Impact factor: 5.087

Review 8.  Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.

Authors:  Guido Sauter; James Lee; John M S Bartlett; Dennis J Slamon; Michael F Press
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

9.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  Arch Pathol Lab Med       Date:  2007       Impact factor: 5.534

10.  Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis.

Authors:  Caterina Marchiò; Maryou B Lambros; Patrizia Gugliotta; Ludovica Verdun Di Cantogno; Cristina Botta; Barbara Pasini; David S P Tan; Alan Mackay; Kerry Fenwick; Narinder Tamber; Gianni Bussolati; Alan Ashworth; Jorge S Reis-Filho; Anna Sapino
Journal:  J Pathol       Date:  2009-09       Impact factor: 7.996

View more
  145 in total

1.  Immunohistochemical profile and morphology in triple - negative breast cancers.

Authors:  Chandrika Rao; Jayaprakash Shetty; Kishan Hl Prasad
Journal:  J Clin Diagn Res       Date:  2013-05-28

2.  Trastuzumab-induced cardiac dysfunction: A 'dual-hit'.

Authors:  Matthew Zeglinski; Ana Ludke; Davinder S Jassal; Pawan K Singal
Journal:  Exp Clin Cardiol       Date:  2011

3.  Pharmacogenomics meets precision cardio-oncology: is there synergistic potential?

Authors:  Jennifer K Hockings; Jessica A Castrillon; Feixiong Cheng
Journal:  Hum Mol Genet       Date:  2020-10-20       Impact factor: 6.150

4.  Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.

Authors:  Raju Khatri; Preeti Shah; Rupa Guha; Feyruz V Rassool; Alan E Tomkinson; Angela Brodie; Anil K Jaiswal
Journal:  Mol Cancer Ther       Date:  2015-05-14       Impact factor: 6.261

5.  Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression.

Authors:  Jonathan Stewart; Jacqueline James; Glenn W McCluggage; Stephen McQuaid; Kenneth Arthur; David Boyle; Paul Mullan; Darragh McArt; Benedict Yan; Gareth Irwin; D Paul Harkin; Lei Zhengdeng; Chee-Wee Ong; Jia Yu; David M Virshup; Manuel Salto-Tellez
Journal:  Mod Pathol       Date:  2014-09-26       Impact factor: 7.842

6.  Lin28 promotes Her2 expression and Lin28/Her2 predicts poorer survival in gastric cancer.

Authors:  Qinchuan Wang; Jichun Zhou; Jufeng Guo; Rongyue Teng; Jianguo Shen; Yasheng Huang; Shuduo Xie; Qun Wei; Wenhe Zhao; Wenjun Chen; Xiaoming Yuan; Yongxia Chen; Linbo Wang
Journal:  Tumour Biol       Date:  2014-08-16

7.  Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas.

Authors:  Zhangjuan Song; Yan Deng; Kangmin Zhuang; Aimin Li; Side Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

8.  Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.

Authors:  Juliann Chmielecki; Jeffrey S Ross; Kai Wang; Garrett M Frampton; Gary A Palmer; Siraj M Ali; Norma Palma; Deborah Morosini; Vincent A Miller; Roman Yelensky; Doron Lipson; Philip J Stephens
Journal:  Oncologist       Date:  2014-12-05

9.  Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors.

Authors:  J Carlsson; L Shen; J Xiang; J Xu; Q Wei
Journal:  Oncol Lett       Date:  2012-10-25       Impact factor: 2.967

Review 10.  Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.

Authors:  Keith T Schmidt; Cindy H Chau; Douglas K Price; William D Figg
Journal:  J Clin Pharmacol       Date:  2016-06-17       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.